Pfizer Inc. $PFE Stock Holdings Lowered by FRG Family Wealth Advisors LLC

Key Points

• FRG Family Wealth Advisors LLC has reduced its stake in Pfizer Inc. by 33.7%, resulting in ownership of 29,509 shares worth approximately $748,000.
• The biopharmaceutical company reported a quarterly earnings of $0.78 per share, exceeding analyst expectations, with revenue reaching $14.65 billion, which is a 10.3% year-over-year increase.
• Pfizer announced a quarterly dividend of $0.43 per share, yielding 7.0%, with a payout ratio currently at 91.49%.

FRG Family Wealth Advisors LLC decreased its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 33.7% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 29,509 shares of the biopharmaceutical company's stock after selling 15,006 shares during the period. FRG Family Wealth Advisors LLC's holdings in Pfizer were worth $748,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Clarity Asset Management Inc. acquired a new stake in Pfizer during the fourth quarter worth about $27,000. Gould Capital LLC grew its holdings in shares of Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 493 shares during the last quarter. GKV Capital Management Co. Inc. acquired a new stake in shares of Pfizer during the 1st quarter worth approximately $27,000. North Capital Inc. bought a new stake in shares of Pfizer in the 1st quarter worth approximately $28,000. Finally, Bayforest Capital Ltd acquired a new position in Pfizer during the 1st quarter valued at approximately $28,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

PFE has been the topic of several analyst reports. Jefferies Financial Group increased their target price on Pfizer from $32.00 to $33.00 and gave the stock a "buy" rating in a research report on Wednesday, May 21st. Morgan Stanley upped their price target on shares of Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a research report on Wednesday, August 6th. Bank of America lifted their price objective on shares of Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. HSBC reduced their target price on shares of Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a research note on Monday, May 19th. Finally, Citigroup boosted their price objective on Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Pfizer has a consensus rating of "Hold" and a consensus price target of $28.12.

Pfizer Price Performance

Shares of PFE stock traded up $0.14 during midday trading on Friday, reaching $24.74. 37,002,549 shares of the company were exchanged, compared to its average volume of 42,996,172. The company's 50 day moving average price is $24.79 and its two-hundred day moving average price is $24.37. The company has a market cap of $140.65 billion, a P/E ratio of 13.16, a PEG ratio of 0.88 and a beta of 0.55. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $30.43. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business had revenue of $14.65 billion during the quarter, compared to analysts' expectations of $13.43 billion. During the same period last year, the firm posted $0.60 earnings per share. The business's revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.0%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's payout ratio is currently 91.49%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.